<DOC>
	<DOCNO>NCT00307307</DOCNO>
	<brief_summary>The primary objective randomize , double blind , placebo control pilot study determine therapy aim lower LDL cholesterol ( HMGCoA reductase inhibitor – simvastatin ) increase HDL cholesterol ( Niaspan ) induce regression carotid atherosclerotic plaque vivo use MRI image technique . MR plaque morphology baseline compare 6 12 month therapy change MR characteristic compare change lipoprotein parameter urinary isoprostanes . The effect moderate LDL reduction , aggressive LDL reduction combination aggressive LDL reduction HDL elevation MRI plaque characteristic compare randomly assign subject ( n=69 ) carotid disease ( &gt; 30 % stenosis ultrasound criterion ) one three treatment arm ; 1 . Simvastatin 20 mg daily placebo Niaspan ( n=23 ) 2 . Simvastatin 80 mg daily placebo Niaspan ( n=23 ) 3 . Simvastatin 20 mg daily active Niaspan ( n=23 ) Treatment group 2 3 roughly equivalent LDL lower synergistic LDL lower effect combination simvastatin Niaspan .</brief_summary>
	<brief_title>Carotid Atherosclerosis Regression Magnetic Resonance Assessment .</brief_title>
	<detailed_description>FULL PROTOCOL 1.0 SYNOPSIS The primary objective randomize , double blind , placebo control pilot study determine therapy aim lower LDL cholesterol ( HMGCoA reductase inhibitor – simvastatin ) increase HDL cholesterol ( Niaspan ) induce regression carotid atherosclerotic plaque vivo use MRI image technique . MR plaque morphology baseline compare 6 12 month therapy change MR characteristic compare change lipoprotein parameter urinary isoprostanes . The effect moderate LDL reduction , aggressive LDL reduction combination aggressive LDL reduction HDL elevation MRI plaque characteristic compare randomly assign subject ( n=69 ) carotid disease ( &gt; 30 % stenosis ultrasound criterion ) one three treatment arm ; 1 . Simvastatin 20 mg daily placebo Niaspan ( n=23 ) 2 . Simvastatin 80 mg daily placebo Niaspan ( n=23 ) 3 . Simvastatin 20 mg daily active Niaspan ( n=23 ) Treatment group 2 3 roughly equivalent LDL lower synergistic LDL lower effect combination simvastatin Niaspan . 2.0 BACKGROUND Atherosclerotic carotid disease large single etiological factor know produce focal cerebral ischemia ( 1 ) . Only small percentage patient asymptomatic carotid atherosclerosis develop stroke majority warning symptom . The degree internal carotid stenosis ultrasound angiography , common method assess risk stroke , poor predictor stroke patient asymptomatic carotid atherosclerosis ( 2 ) clinical risk factor high prevalence low relative risk stroke patient . Most plaque rupture occur unstable lipid rich plaque thin fibrous cap weaken inflammation apoptosis ( 3 ) . Thus , morphological characteristic carotid plaque may provide important information regard ischemic risk carotid lesion . We , others , use high resolution MR imaging ( 4-6 ) differentiate carotid plaque element lipid core , fibrous cap hemorrhage ultimate goal determine ischemic potential carotid atherosclerotic plaque . Lipid lower therapy statin consider standard treatment patient atherosclerosis hypercholesterolemia ( 7-9 ) . Statin therapy reduces LDL cholesterol level , cardiovascular event death retard progression atherosclerosis assess noninvasive intima-media thickness ( IMT ) carotid ultrasound ( 10 ) . However , optimal degree LDL cholesterol lower statin patient atherosclerosis remain unclear ( 7,8 ) – thus number ongoing large clinical trial compare effect low dose high dos statins cardiovascular effect patient coronary atherosclerosis ( eg “ Treatment New Targets ” ) . Low HDL cholesterol independent risk factor development progression atherosclerosis ( 11 ) . Niacin one effective therapy significantly elevate HDL level show reduce cardiovascular event patient know coronary atherosclerosis prior development statin drug ( 12,13 ) . Increased HDL think promote reverse cholesterol transport peripheral tissue include atherosclerotic plaque ( 14-16 ) . Presently , niacin consider standard therapy patient know atherosclerosis . Niaspan new controlled-release form niacin administer daily , well tolerate crystalline niacin give 3 time day ( 17,18 ) . It show result great 30 % increase HDL cholesterol preliminary data suggest safe effective associate hepatotoxicity ( 19 ) . In proposed study patient ( n=60 ) carotid disease ( &gt; 30 % stenosis ultrasound criterion ) randomly assign one three treatment arm ; 1 . Simvastatin 20 mg daily placebo Niaspan ( n=23 ) 2 . Simvastatin 80 mg daily placebo Niaspan ( n=23 ) 3 . Simvastatin 20 mg daily active Niaspan ( n=23 ) Thus , effect Simvastatin 10 mg ( moderate LDL reduction ) , Simvastatin 80 mg ( aggressive LDL reduction ) combination Simvastatin Niaspan ( aggressive LDL reduction HDL elevation ) MRI plaque characteristic compare . 3.0 OBJECTIVES The primary objective randomize , double blind , placebo control pilot study determine therapy aim lower LDL cholesterol ( HMGCoA reductase inhibitor – statin ) increase HDL cholesterol ( Niaspan ) induce regression carotid atherosclerotic plaque vivo use MRI image technique . MR plaque morphology baseline compare 6 12 month therapy change MR characteristic compare change lipoprotein parameter urinary isoprostanes . 3.1 Primary End-Point The primary end-point change carotid plaque volume MRI 12 month treatment . 3.2 Secondary End-Points 1 . – change carotid plaque lipid content MRI 12 month 2 . – change lipid parameter 12 month 3 . – change urinary isoprostane excretion 12 month 4.0 STUDY DESIGN 4.1 Description This study randomize , double-blind placebo control . Sixty patient randomly assign ( 1 ) Simvastatin 20 mg placebo Niaspan , ( 2 ) Simvastatin 80 mg placebo Niaspan ( 3 ) Simvastatin 20 mg active Niaspan . The study involve 6 outpatient visit General Clinical Research Center ( GCRC ) Hospital University Pennsylvania . Each visit last approximately 2 hour . 4.2 Number Subjects Sixty nine ( 69 ) subject know carotid atherosclerosis investigate . 5.0 STUDY POPULATION Source subject Subjects carotid disease , identify ( 1 ) routine carotid ultrasound examination vascular laboratory University Pennsylvania Health System VA Medical Center , ( 2 ) local advertisement invite participate study . Subjects contact letter invite participate study . Subjects screen accord follow inclusion exclusion criterion ; Inclusion Criteria Age &gt; 18 &lt; 90 year Capacity give write informed consent Carotid stenosis &gt; 30 % ultrasound criterion LDL cholesterol level &gt; 100mg/dl Systolic BP &lt; 170 diastolic BP &lt; 100 rest condition Negative pregnancy test female child-bearing potential Exclusion criterion Recent ( &lt; 3 month ) history stroke , transient ischemic attack , myocardial infarction , unstable angina critical limb ischemia , Contraindications MRI ( claustrophobia , presence pacemaker , defibrillator , metal foreign body ) , History side effect/adverse reaction HMGCoA reductase inhibitor , Niaspan niacin , Poorly control diabetes ( HbA1c &gt; 8 % ) , History myositis , liver disease abnormal LFTs , Need combination therapy control severe hyperlipidemia , Abnormal LFT ( &gt; 2 fold upper limit normal ) , Active infection malignancy . 6.0 STUDY PROCEDURES The study involve 6 outpatient visit General Clinical Research Center ( GCRC ) Hospital University Pennsylvania . Each visit last approximately 2 hour . 6.1 Pre-treatment Period All subject ask come GCRC screen visit . During visit , complete medical history physical examination perform . Dosage chronic medication record . Supine rest blood pressure , electrocardiogram follow fast routine laboratory study perform ; Hematology ; hemoglobin , hematocrit , MCV , white blood count platelet count Blood chemistry ; sodium , potassium , chloride , creatinine , fast glucose , albumin , alkaline phosphatase , total bilirubin , AST , ALT , uric acid total cholesterol , LDL , HDL , triglycerides lipoprotein ( ) HbA1c . Urinalysis Urinary HCG - woman child bear potential . Eligible subject undergo full dietary assessment GCRC research dietician use quantitative questionnaire . Subjects instruct comply recommend AHA dietary guideline dietary intake macronutrients include fat cholesterol similar across subject . Dietary compliance monitor baseline study visit 24-hour recall dietary intake . The Dietary Analysis System ( DIETSYS ) use analyze food frequency questionnaire Food Processor Plus ( ver 6.0 ) use analyze dietary recall . 6.2 Concurrent Treatment The use concurrent medication restrict study period . Indeed , aspirin use antihypertensive therapy encourage appropriate . Lipid lower medication , study stop prior randomization . For example HMGCoA reductase inhibitor replace simvastatin time randomization . 6.3 Treatment Period Eligible subject ask collect 12-hour urine sample prior randomization bring GCRC morning randomization process stored analysis . Baseline blood sample collect hematology , chemistry lipoprotein analysis per screen . Subjects undergo micro MRI scan carotid artery MRI center adjacent GCRC . A subset volunteer ( n=10 ) ask undergo second baseline MRI scan within week first scan order determine reproducibility quantitative MRI technique . Subjects randomize double blind manner ( 1 ) Simvastatin 20 mg placebo Niaspan , ( 2 ) Simvastatin 80 mg placebo Niaspan ( 3 ) Simvastatin 20 mg active Niaspan . Simvastatin tablet provide Merck Pharmaceuticals , manufacturer Simvastatin . Niaspan tablet ( 500mg ) match placebo provide KOS , company manufacture Niaspan . Niaspan titrate accord clinical guideline – 500 mg bedtime 1 month , 1000 mg bedtime next month finally 2000 mg bedtime rest study . At randomization visit , specific instruction titration Niaspan placebo ( give match tablet identical way ) discuss give subject one-month supply study drug . Both Niaspan ( KOS Pharmaceuticals ) simvastatin ( Zocor ; Merck Pharmaceuticals ) commercially available drug FDA approve management hyperlipidemia dos , formulation route administration propose study . Return visit schedule 1 , 3 , 6 12 month . At visit history , physical exam blood testing ( hematology , chemistry , fast lipoprotein ) undertake . In addition , urine collection MRI study perform 6 12 month . Known adverse effect , flush muscle cramp screen visit . Subjects discontinue study follow reason ; 1. intolerable side effect study medication 2. increase either ALT AST great 3 time upper limit normal 3 . HbA1c &gt; 9 % 4. uric acid &gt; 11.0 5. pregnancy Eligible subject ask increase study medication 2000mg daily bedtime second month . Every attempt make titrate Niaspan/placebo 2000mg per day , possible subject maintain maximal achievable dose . The duration study 12 month . All assessment make personnel blind study treatment . 6.4 Duration Study The duration entire study approximately 18 month . Actual study drug treatment 12 month duration . Each subject undergo screen approximately 2 week prior randomization anticipate subject enrol 6 month period . 6.5 Premature Withdrawal Study A volunteer may withdraw trial follow reason : - Any adverse event think warrant withdrawal investigator , - Poor compliance think warrant withdrawal investigator , - Volunteer ’ desire withdraw study time , - Protocol entry criterion violation , - Pregnancy . The reason withdrawal final outcome case adverse event document Case Report Form . Subjects complete study replace . 7.0 EFFICACY ASSESSMENT 7.0 Variables measure Efficacy Assessment Magnetic Resonance Imaging Carotid Atherosclerotic Plaques : A variety MRI technique optimize permit sufficient resolution determine size composition atherosclerotic plaque . These include `` black-blood '' image technique , fast spin echo sequence , fat suppression technique addition customize coil ( 4-6 ) . Customized surface coil construct improve signal-to-noise ratio . While coil sequence FDA approve custom build , fall category “ non-significant risk device ” . These technique already establish purpose MRI center Hospital University Pennsylvania . The image protocol consist combination black blood ( fast spin echo double inversion recovery fast spin echo sequence ) bright blood imaging ( time-of-flight MRA sequence ) achieve optimal contrast arterial lumen vessel wall . Specifically , follow sequence obtain : ( 1 ) 3D time flight ( TOF ) MRA carotid bifurcation ; ( 2 ) axial T1-weighted fast spin echo ; ( 3 ) axial proton density-weighted weight double inversion recovery fast spin echo ( DIR-FSE ) plaque ; ( 4 ) axial T2-weighted weighted DIR-FSE plaque . Total plaque volume quantify follow ; Plaque volume = ( computer assist calculation region interest-ROI ) x ( slice thickness ) x ( . slice ) . Plaque composition estimate use establish image criterion 4 image contrast weighting ( Table 1 ) . Table 1 Criteria use identification plaque constituent . TOF T1-W PD-W T2-W Calcification Low Low Low Low Hemorrhage High High/Moderate Variable Variable Lipid core Moderate High High Variable Fibrous cap Moderate/Low Moderate High Variable Note : Intensity descriptor relative intensity sternocleidomastoid muscle . Lipoprotein Determination : Total cholesterol , LDL cholesterol , HDL cholesterol , lipoprotein ( ) triglyceride level determine standardize technique routine chemistry laboratory Hospital University Pennsylvania . Urinary Isoprostanes : Urinary isoprostanes measure mass spectrometry / gas chromatography ( GC / MS ) previously describe PI ( 20 ) . Following addition deuterated isoprostane internal standard , urine sample extract aqueous matrix solid phase extraction technique , purify thin layer chromatography , derivatized , analyze GC / MS negative ion chemical ionization ( NICI ) mode . Quantification accomplish take ratio area peak ion represent endogenous compound internal standard.All subject complete study consider evaluable efficacy assessment . 7.2 Criteria Evaluability Efficacy Assessment All subject complete study consider evaluable efficacy assessment . 8.0 SAFETY ASSESSMENT 8.1 Variables Measured Safety Assessment Safety measure monitor include 1. symptom ( flush , abdominal pain , tiredness ) 2. transaminase 3 . HbA1c 4. uric acid 8.2 Criteria Evaluability Safety Assessment All subject enter trial consider evaluable safety assessment . 9.0 STATISTICAL CONSIDERATIONS There currently data available effect therapy carotid atherosclerotic plaque morphology use MRI base sample size estimation . Therefore , sample size base desire acquire pilot data allow determination actual number require study examine MR characteristic clinical endpoint . A sample size 69 ( 23 subject per arm ) provide 80 % power detect hypothesize difference ( 15 % ) primary endpoint ( plaque volume ) 2 different treatment arm alpha 0.05 . The number subject need future full-scale clinical study dependent coefficient variation repeat baseline quantitative MRI scan change plaque volume ( primary end-point ) follow intervention . These parameter define propose pilot study . 10.0 DATA COLLECTION , MONITORING AND AE REPORTING 10.1 Case Report Forms Case Report Forms ( CRFs ) provide subject . Subjects must identify name study document . Subjects identify Patient Identification Number ( PIN ) Study Identification Number ( SID ) . All data CRF legibly record black ink type . Corrections make strike incorrect entry single line add correct information adjacent . The correction initial dated investigator designate qualified individual . Any requested information obtain specify protocol indicate CRFs “ do ” ( ND ) “ applicable ” ( NA ) . 10.2 Data Management The CRF design data management perform PI research assistant . 10.3 Monitoring The PI review research record accuracy , completeness legibility . The investigator designate qualified individual make study document ( eg consent form , drug distribution form , case report form ) pertinent hospital clinic record available inspection Food Drug Administration ( FDA ) conformation data . 10.4 Adverse Experience ( AE ) Reporting Adverse Experiences ( AEs ) monitor throughout study event record Adverse Experience Case Report Forms . An AE define unfavorable unintended change structure , function chemistry body temporally associate use study medication , whether consider related use product . The AEs grade three-point scale ( mild , moderate severe ) drug relationship assign . Any serious unexpected adverse event report within 24 hour FDA IRB University Pennsylvania . Adverse event define serious fatal , life-threatening result in-patient hospitalization prolongation hospitalization . In addition occurrence malignancy always consider serious adverse advent . Adverse event consider unexpected occurrence , severity frequency previously report concomitance Niaspan HMGCoA reductase inhibitor therapy . 11.0 ETHICAL CONSIDERATIONS 11.1 Institutional Review Board ( IRB ) The study protocol review committee Studies involve Human Beings University Pennsylvania . A copy letter approval correspondence IRB retain investigator . 11.2 Informed Consent Written inform consent obtain every volunteer participate study adequate explanation object study possibly adverse effect drug treatment . 11.3 Subject Confidentiality The medical information gather study treat confidentially except may require law . Regulatory authority , include US Food Drug Administration , might review medical record verify accuracy information collect . Subjects identify name study document , result publish subject ’ identity disclose . REFERENCES 1 . Gelabert HA Moore WS . Carotid endarterectomy : current status . Curr Prob Surg 1991 ; XXVIII : 187-262 . 2 . Moneta GL , Taylor DC , Zierler RE , Kazmers A , Beach K Stradness DE . Asymptomatic high grade internal carotid carotid artery stenosis : stratification accord risk factor duples spectral analysis possible . J Vasc Surg 1989 ; 10 : 475 . 3 . Libby P , Li H. Vascular cell adhesion molecule-1 smooth muscle cell activation atherogenesis . J Clin Invest 1993 ; 92 : 538-539 4 . Skinner MP , Yuan C , Mitsumori L , Hayes CE , Raines EW , Nelson JA , Ross R. Serial magnetic-resonance image experimental atherosclerosis detects lesion fine structure , progression complication vivo . Nature Medicine 1995 ; 1 : 69-73 . 5 . Toussaint J-F , Southern JF , Fuster V , Kantor HL . T2-weighted contrast NMR characterization human atherosclerosis . Arterioscler Thromb Vasc Biol 1995 ; 15 : 1533-42 . 6 . Toussaint J-F , LaMuraglia GM , Southern JF , Fuster V , Kantor HL . Magnetic resonance image lipid , fibrous , calcified hemorrhagic thrombotic component human atherosclerosis vivo . Circulation 1996 ; 94 : 932-938 . 7 . Scandinavian Simvastatin Survival Study Group . Randomized trial cholesterol lower 4444 patient coronary heart disease : Scandinavian Simvastatin Survival Study ( 4S ) . Lancet 1994 ; 344 : 1383-89 . 8 . Ridker , P. M. , N. Rifai , M. A. Pfeffer , F. M. Sacks , L. A. Moye , S. Goldman , G. C. Flaker , E. Braunwald . Inflammation , pravastatin , risk coronary event myocardial infraction patient average cholesterol level . Cholesterol recurrents event ( CARE ) investigatiors . Circulation 1998 ; 98:839-844 . 9 . Jukema JW , Bruschke AVG , van Boven AJ et al ; behalf REGRESS Study Group . Effects lipid lower pravastatin progression regression coronary artery disease symptomatic men normal moderately elevated serum cholesterol level . The regression growth evaluation statin study ( REGRESS ) . Circulation 1995 ; 91 : 2528-40 . 10 . Crouse JR , Byington RP , Bond MG , Espeland MA , Craven TE , Sprinkle JW , McGovern ME , Furberg CD . Pravastatin , lipids atherosclerosis carotid artery ( PLAC-II ) . Am J Cardiol 1995 ; 75 : 455-9 . 11 . Vega , G. L. S. M. Grundy . Hypoalphalipoproteinemia ( low high density lipoprotein ) risk factor coronary heart disease . Curr . Opin . Lipidol . 1996 ; 7:209-216 . 12 . Canner , P. L. , K. G. Berge , N. K. Wenger , J. Stamler , L. Friedman , R. J. Prineas , W. Friedwald . Fifteen year mortality Coronary Drug Project patient : Long term benefit niacin . J Am Coll Cardiol 1986 ; 8:1245-1255 . 13 . Blankenhorn DH , Nessim SA , Johnson RL , Sanmarco ME , Azen SP , Cashin-Hemphill L. Beneficial effect colestipol-niacin therapy coronary atherosclerosis coronary venous bypass graft . JAMA 1987 ; 257 : 3233-3240 . 14 . Reichl , D. N. E. Miller . Pathophysiology reverse cholesterol transport . Insights inherit disorder lipoprotein metabolism . Arteriosclerosis 1989 ; 9 : 785-797 . 15 . Plump AS , Scott CJ , Breslow JL . Human apolipoprotein A-I gene expression increase high density lipoprotein suppress atherosclerosis apolipoprotein E-deficient mouse . Proc Natl Acad Science 1994 ; 91 : 9607-9611 . 16 . Eriksson M , Carlson LA , Miettinen TA , Angelin B. Stimulation fecal steroid excretion infusion recombinant proapolipoprotein A-I . Potential reverse cholesterol transport human . Circulation 1999 ; 100 : 594-598 . 17 . Rosenson , R. S. 1993 . Low level high-density lipoprotein cholesterol ( hypoalphalipoproteinemia ) : approach management . Arch Intern Med 1993 ; 153:1528-1538 . 18 . Alderman JD , Pasternak RC , Sacks FM , Smith HS , Monrad ES , Grossman W. Effect modify , well tolerate niacin regimen serum total cholesterol , high density lipoprotein cholesterol high density lipoprotein ratio . Am J Cardiol 1989 ; 64 : 725-729 . 19 . Morgan , J. M. , D. M. Capuzzi , J. R. Guyton , R. M. Centor , R. Goldberg , D. C. Robbins , D. Dipette , S. Jenkins , S. Marcovina . Treatment effect Niaspan , controlled-release niacin , patient hypercholesterolemia : placebo-controlled trial . J Cardiovasc Pharm Ther 1996 ; 1:195-202 . 20 . Reilly MP , Pratico D , Delanty N , DiMinno G , Tremoli E , Rader D , Kapoor S , Lawson JA , Rokach J , FitzGerald GA . Increased biosynthesis distinct F2-isoprostanes hypercholesterolemia . Circulation 1998 ; 98 : 2822-2828 .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Age &gt; 18 &lt; 90 year Capacity give write informed consent Carotid stenosis &gt; 30 % ultrasound criterion LDL cholesterol level &gt; 100mg/dl Systolic BP &lt; 170 diastolic BP &lt; 100 rest condition Negative pregnancy test female childbearing potential Recent ( &lt; 3 month ) history stroke , transient ischemic attack , myocardial infarction , unstable angina critical limb ischemia Contraindications MRI ( claustrophobia , presence pacemaker , defibrillator , metal foreign body ) History side effect/adverse reaction HMGCoA reductase inhibitor Niaspan niacin Poorly control diabetes ( HbA1c &gt; 8 % ) History myositis , liver disease abnormal LFTs Need combination therapy control severe hyperlipidemia Abnormal LFT ( &gt; 2 fold upper limit normal ) Active infection malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>niacin</keyword>
	<keyword>MR imaging</keyword>
</DOC>